1. Treatment with sotatercept decreased pulmonary vascular resistance in patients with pulmonary arterial hypertension.
2. Sotatercept caused adverse side effects of thrombocytopenia and increased hemoglobin level.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Pulmonary arterial hypertension (PAH) is driven by reduced bone morphogenic protein receptor type 2 (BMP2) and increased activin signaling...